论文部分内容阅读
目的:观察口服十一酸睾酮胶丸联合麒麟丸治疗男性迟发性性腺功能减退症(LOH)患者的临床疗效。方法:符合纳入标准的63例LOH患者随机分为对照组和试验组,对照组口服十一酸睾酮胶丸,试验组口服十一酸睾酮胶丸和麒麟丸。十一酸睾酮胶丸用法:80 mg/次,1次/d,连续服用3个月;麒麟丸用法:6 g/次,3次/d,连续服用3个月。比较组内和组间治疗前后的IIEF-5评分、老年男性症状问卷(AMS)评分及血清总睾酮(TT)水平的变化。结果:两组间各项数据无明显差异(P>0.05)。但治疗后试验组IIEF-5评分(21.7±5.8)分和TT值(16.7±2.2)nmol/L均显著高于对照组(15.9±4.7)分和(13.1±2.8)nmol/L(P<0.05);且AMS评分(20.7±5.7)分显著低于对照组(31.3±6.5)分(P<0.05)。结论:麒麟丸联合十一酸睾酮胶丸治疗LOH的疗效比单用十一酸睾酮胶丸治疗效果更显著,且不增加不良反应发生率,有一定的临床应用前景。
Objective: To observe the clinical efficacy of oral administration of testosterone undecanoate combined with unicorn pills in the treatment of male patients with delayed hypogonadism (LOH). Methods: Sixty-three patients with LOH meeting the inclusion criteria were randomly divided into a control group and a test group. The control group received testosterone undecanoate capsules. The test group received testosterone undecanoate capsules and unicin pills. Undecanoate testosterone capsules Usage: 80 mg / time, 1 time / d, taking 3 consecutive months; unicorn pill usage: 6 g / time, 3 times / d, taking 3 consecutive months. The changes of IIEF-5 score, AMS score and total serum testosterone (TT) level before and after treatment in both groups were compared. Results: There was no significant difference between the two groups (P> 0.05). However, the scores of IIEF-5 (21.7 ± 5.8) and TT (16.7 ± 2.2) nmol / L in the experimental group were significantly higher than those in the control group (15.9 ± 4.7) and (13.1 ± 2.8) nmol / L after treatment 0.05). The AMS score (20.7 ± 5.7) was significantly lower than that of the control group (31.3 ± 6.5) (P0.05). Conclusion: Kirin pills combined with testosterone undecanoate capsules for the treatment of LOH than single acid testosterone capsules treatment effect is more significant, and does not increase the incidence of adverse reactions, have some clinical application prospects.